Michael Coleman, professor at the London School of Hygiene and Tropical Medicine, and one of the lead authors of the study told TOI that one reason for the low survival rates in India could be that equitable access to early diagnosis and optimal treatment is not yet available for all people in India.
"Some of the most advanced medical facilities in the world can be found in Mumbai (for example), but they are out of reach of the vast majority of the Indian population," he said.
"The inequality…
This new class of drugs unleashes the body's immune system to fight tumors. This seems to solve a century-old mystery of how cancerous cells manage to evade the body's immune system. The drug which Merck will sell under the name of Keytruda was approved by patients with advanced melanoma who have exhausted other therapies.
Community
Condition